Brain Neurotransmitter Receptor Binding and Neuroleptic Drugs

Ian Creese, Solomon H Snyder

Research output: Contribution to journalArticle

Abstract

The molecular mechanism of a therapeutic drug is suggested by the biochemical event that correlates best with clinical potency. Binding is the recognition site of a receptor. The striatal dopamine-sensitive adenylate cyclase, encompasses both a recognition and an effector unit. The neuroleptic drugs exert their therapeutic actions and induce extrapyramidal side effects by blocking the dopamine receptors in the brain. Autonomic sympatholytic effect, such as orthostatic hypotension and sedation, are among the most prominent untoward actions of the neuroleptic drugs. The norepinephrine-sensitive adenylate cyclase in rat limbic forebrain indicates that the neuroleptics have a high affinity for norepinephrine areceptor sites. Stereospecificity and correlations between the clinical and the biochemical effects reveal the biochemical basis of neuroleptic drug action. Droperidol is one-fourth as potent as spiroperidol at the dopamine receptor. There is poor correlation between neuroleptic affinity for H-haloperidol binding sites and norepinephrine and epinephrine toxicity. While molecular modeling indicates how phenothiazines assume the preferred conformation of dopamine, the conformation of butyrophenones at their receptor sites is unclear. In extrapyramidal side effects and muscarinic binding, dopamine receptor blockade in the corpus striatum is responsible for the extrapyramidal side effects of neuroleptic therapy, while dopamine receptor blockade in the limbic forebrain, regions associated with emotional behaviors, is responsible for the antischizophrenic efficacy of the neuroleptic agents.

Original languageEnglish (US)
Pages (from-to)249-259
Number of pages11
JournalAnnual Reports in Medicinal Chemistry
Volume12
Issue numberC
DOIs
StatePublished - Jan 1 1977

Fingerprint

Neurotransmitter Receptor
Antipsychotic Agents
Brain
Dopamine Receptors
Corpus Striatum
Norepinephrine
Prosencephalon
Adenylyl Cyclases
Conformations
Dopamine
Butyrophenones
Sympatholytics
Autonomic Agents
Droperidol
Phenothiazines
Spiperone
Orthostatic Hypotension
Molecular modeling
Haloperidol
Cholinergic Agents

ASJC Scopus subject areas

  • Biochemistry
  • Organic Chemistry

Cite this

Brain Neurotransmitter Receptor Binding and Neuroleptic Drugs. / Creese, Ian; Snyder, Solomon H.

In: Annual Reports in Medicinal Chemistry, Vol. 12, No. C, 01.01.1977, p. 249-259.

Research output: Contribution to journalArticle

@article{860b9967b9804061a5522e8972f24082,
title = "Brain Neurotransmitter Receptor Binding and Neuroleptic Drugs",
abstract = "The molecular mechanism of a therapeutic drug is suggested by the biochemical event that correlates best with clinical potency. Binding is the recognition site of a receptor. The striatal dopamine-sensitive adenylate cyclase, encompasses both a recognition and an effector unit. The neuroleptic drugs exert their therapeutic actions and induce extrapyramidal side effects by blocking the dopamine receptors in the brain. Autonomic sympatholytic effect, such as orthostatic hypotension and sedation, are among the most prominent untoward actions of the neuroleptic drugs. The norepinephrine-sensitive adenylate cyclase in rat limbic forebrain indicates that the neuroleptics have a high affinity for norepinephrine areceptor sites. Stereospecificity and correlations between the clinical and the biochemical effects reveal the biochemical basis of neuroleptic drug action. Droperidol is one-fourth as potent as spiroperidol at the dopamine receptor. There is poor correlation between neuroleptic affinity for H-haloperidol binding sites and norepinephrine and epinephrine toxicity. While molecular modeling indicates how phenothiazines assume the preferred conformation of dopamine, the conformation of butyrophenones at their receptor sites is unclear. In extrapyramidal side effects and muscarinic binding, dopamine receptor blockade in the corpus striatum is responsible for the extrapyramidal side effects of neuroleptic therapy, while dopamine receptor blockade in the limbic forebrain, regions associated with emotional behaviors, is responsible for the antischizophrenic efficacy of the neuroleptic agents.",
author = "Ian Creese and Snyder, {Solomon H}",
year = "1977",
month = "1",
day = "1",
doi = "10.1016/S0065-7743(08)61564-X",
language = "English (US)",
volume = "12",
pages = "249--259",
journal = "Annual Reports in Medicinal Chemistry",
issn = "0065-7743",
publisher = "Academic Press Inc.",
number = "C",

}

TY - JOUR

T1 - Brain Neurotransmitter Receptor Binding and Neuroleptic Drugs

AU - Creese, Ian

AU - Snyder, Solomon H

PY - 1977/1/1

Y1 - 1977/1/1

N2 - The molecular mechanism of a therapeutic drug is suggested by the biochemical event that correlates best with clinical potency. Binding is the recognition site of a receptor. The striatal dopamine-sensitive adenylate cyclase, encompasses both a recognition and an effector unit. The neuroleptic drugs exert their therapeutic actions and induce extrapyramidal side effects by blocking the dopamine receptors in the brain. Autonomic sympatholytic effect, such as orthostatic hypotension and sedation, are among the most prominent untoward actions of the neuroleptic drugs. The norepinephrine-sensitive adenylate cyclase in rat limbic forebrain indicates that the neuroleptics have a high affinity for norepinephrine areceptor sites. Stereospecificity and correlations between the clinical and the biochemical effects reveal the biochemical basis of neuroleptic drug action. Droperidol is one-fourth as potent as spiroperidol at the dopamine receptor. There is poor correlation between neuroleptic affinity for H-haloperidol binding sites and norepinephrine and epinephrine toxicity. While molecular modeling indicates how phenothiazines assume the preferred conformation of dopamine, the conformation of butyrophenones at their receptor sites is unclear. In extrapyramidal side effects and muscarinic binding, dopamine receptor blockade in the corpus striatum is responsible for the extrapyramidal side effects of neuroleptic therapy, while dopamine receptor blockade in the limbic forebrain, regions associated with emotional behaviors, is responsible for the antischizophrenic efficacy of the neuroleptic agents.

AB - The molecular mechanism of a therapeutic drug is suggested by the biochemical event that correlates best with clinical potency. Binding is the recognition site of a receptor. The striatal dopamine-sensitive adenylate cyclase, encompasses both a recognition and an effector unit. The neuroleptic drugs exert their therapeutic actions and induce extrapyramidal side effects by blocking the dopamine receptors in the brain. Autonomic sympatholytic effect, such as orthostatic hypotension and sedation, are among the most prominent untoward actions of the neuroleptic drugs. The norepinephrine-sensitive adenylate cyclase in rat limbic forebrain indicates that the neuroleptics have a high affinity for norepinephrine areceptor sites. Stereospecificity and correlations between the clinical and the biochemical effects reveal the biochemical basis of neuroleptic drug action. Droperidol is one-fourth as potent as spiroperidol at the dopamine receptor. There is poor correlation between neuroleptic affinity for H-haloperidol binding sites and norepinephrine and epinephrine toxicity. While molecular modeling indicates how phenothiazines assume the preferred conformation of dopamine, the conformation of butyrophenones at their receptor sites is unclear. In extrapyramidal side effects and muscarinic binding, dopamine receptor blockade in the corpus striatum is responsible for the extrapyramidal side effects of neuroleptic therapy, while dopamine receptor blockade in the limbic forebrain, regions associated with emotional behaviors, is responsible for the antischizophrenic efficacy of the neuroleptic agents.

UR - http://www.scopus.com/inward/record.url?scp=85023502181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023502181&partnerID=8YFLogxK

U2 - 10.1016/S0065-7743(08)61564-X

DO - 10.1016/S0065-7743(08)61564-X

M3 - Article

AN - SCOPUS:85023502181

VL - 12

SP - 249

EP - 259

JO - Annual Reports in Medicinal Chemistry

JF - Annual Reports in Medicinal Chemistry

SN - 0065-7743

IS - C

ER -